RxDoctor Payments Data

Djordje Atanackovic, MD

Hematology · Baltimore, MDNPI 1417384694

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,350 of the $11,441 with a category attached, or 90.5%. Every reported general payment came from a single manufacturer, Sanofi.

$11,441in general payments, 2019–2025

Across 7 payments — averaging $1634.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$11K
$982,981in research payments, 2019–2025

Across 20 payments — averaging $49,149 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$973K
  • Genentech, Inc.$10K

What the payments were for

  • Consulting fees$10,35090%
  • Travel & lodging$9769%
  • Food & beverage$1151%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi7$11,441

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,441 in reported general payments places this provider in the 75th percentile of 28 hematology providers in Maryland.

See all hematology providers in Maryland

Medicare billing

Part B allowed, 2024
$45,749
Medicare patients
77
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide13$269,558
Acyclovir15$256
Dexamethasone13$67

Paid to pharmacies, not to this prescriber.

Other hematology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →